Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma
Objective: Evaluate the safety of albuterol multidose dry powder inhaler (MDPI), a novel, inhalation-driven device that does not require coordination of actuation with inhalation, in patients with persistent asthma. Methods: We report pooled safety data from two 12-week, multicenter, randomized, do...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Taylor & Francis
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819808/ |